SCHEMBL1102544

SCHEMBL1102544

c1ccc2c(c1)CCc1ccccc1N2c1c2ccccc2c(N2c3ccccc3CCc3ccccc32)c2cnccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 2/20 0.38
NR4A1 P22736 1/20 0.38
HSD17B10 Q99714 1/20 0.37
HTR2C P28335 1/20 0.36
MAOA P21397 5/20 0.36
MAOB P27338 5/20 0.36
ACHE P22303 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
IKBKB O14920 1/20 0.36
AURKA O14965 1/20 0.36
CHUK O15111 1/20 0.36
PIM1 P11309 1/20 0.36
TOP1 P11387 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102651 0.90 CYP11B1 (0.36) STAT3POLBALOX15NR4A1HSD17B10
SCHEMBL1102505 0.90 HPGD (0.38) STAT3POLBHTR2CMAOAMAOB
SCHEMBL1102915 0.85 TNF (0.40) POLBHSD17B10SMN1; SMN2ALDH1A1KDM4E
SCHEMBL1102785 0.83 CYP11B1 (0.39) TDO2CYP11B1CYP11B2CYP19A1MEN1
SCHEMBL1102506 0.80 ACHE (0.45) MAOAMAOBACHESMN1; SMN2ALDH1A1
SCHEMBL1102517 0.80 ADRA2A (0.38) MAOAMAOBACHESMN1; SMN2ALDH1A1
SCHEMBL1102734 0.80 P2RX4 (0.39) POLBHSD17B10MAOAMAOBACHE
SCHEMBL16314377 0.79 MPO (0.31) MAOAMAOBACHESMN1; SMN2ALDH1A1
SCHEMBL1102546 0.79 MAOA (0.39) POLBHSD17B10MAOAMAOBACHE
SCHEMBL1102659 0.78 ROCK1 (0.48) STAT3POLBHSD17B10SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 STAT3 3555/4885POLB 2825/4885ALOX15 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.